Merit Medical Systems, Inc. (NASDAQ:MMSI) Shares Sold by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. decreased its position in shares of Merit Medical Systems, Inc. (NASDAQ:MMSI) by 5.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 28,681 shares of the medical instruments supplier’s stock after selling 1,635 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Merit Medical Systems were worth $2,179,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. State of Wyoming acquired a new position in Merit Medical Systems during the second quarter worth approximately $28,000. Altshuler Shaham Ltd acquired a new position in Merit Medical Systems during the fourth quarter worth approximately $26,000. Valued Wealth Advisors LLC acquired a new position in Merit Medical Systems during the fourth quarter worth approximately $29,000. Tompkins Financial Corp acquired a new position in shares of Merit Medical Systems in the fourth quarter valued at approximately $38,000. Finally, Belpointe Asset Management LLC increased its holdings in shares of Merit Medical Systems by 53.8% in the first quarter. Belpointe Asset Management LLC now owns 500 shares of the medical instruments supplier’s stock valued at $37,000 after purchasing an additional 175 shares during the period. Institutional investors and hedge funds own 99.66% of the company’s stock.

Insiders Place Their Bets

In other Merit Medical Systems news, CFO Raul Jr. Parra sold 6,480 shares of the business’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $73.95, for a total transaction of $479,196.00. Following the sale, the chief financial officer now directly owns 12,007 shares in the company, valued at $887,917.65. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Merit Medical Systems news, CFO Raul Jr. Parra sold 6,480 shares of the business’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $73.95, for a total transaction of $479,196.00. Following the sale, the chief financial officer now directly owns 12,007 shares in the company, valued at $887,917.65. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director F. Ann Millner sold 20,000 shares of the business’s stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $80.00, for a total value of $1,600,000.00. Following the completion of the transaction, the director now directly owns 29,960 shares of the company’s stock, valued at $2,396,800. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 69,637 shares of company stock worth $5,351,673. 3.70% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on MMSI shares. Canaccord Genuity Group boosted their target price on Merit Medical Systems from $102.00 to $112.00 and gave the company a “buy” rating in a report on Thursday, February 29th. Raymond James boosted their target price on Merit Medical Systems from $84.00 to $89.00 and gave the company an “outperform” rating in a report on Tuesday, January 30th. Oppenheimer boosted their target price on Merit Medical Systems from $82.00 to $87.00 and gave the company an “outperform” rating in a report on Thursday, February 29th. Needham & Company LLC reissued a “buy” rating and issued a $88.00 target price on shares of Merit Medical Systems in a report on Thursday, April 11th. Finally, CL King assumed coverage on Merit Medical Systems in a report on Thursday, April 11th. They issued a “buy” rating and a $88.00 target price on the stock. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, Merit Medical Systems has a consensus rating of “Moderate Buy” and a consensus price target of $92.50.

Merit Medical Systems Stock Up 1.5 %

Merit Medical Systems stock opened at $72.03 on Friday. The stock’s 50 day moving average price is $75.08 and its 200 day moving average price is $73.50. The company has a debt-to-equity ratio of 0.68, a current ratio of 5.45 and a quick ratio of 3.95. The company has a market cap of $4.18 billion, a PE ratio of 44.46, a price-to-earnings-growth ratio of 1.99 and a beta of 0.89. Merit Medical Systems, Inc. has a 1-year low of $62.58 and a 1-year high of $85.62.

Merit Medical Systems (NASDAQ:MMSI) last posted its earnings results on Wednesday, February 28th. The medical instruments supplier reported $0.81 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.04. The company had revenue of $324.52 million for the quarter, compared to the consensus estimate of $320.66 million. Merit Medical Systems had a return on equity of 14.63% and a net margin of 7.51%. Merit Medical Systems’s quarterly revenue was up 10.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.79 earnings per share. On average, sell-side analysts predict that Merit Medical Systems, Inc. will post 3.31 EPS for the current fiscal year.

Merit Medical Systems Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.